NCT01740388

Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis

A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 136 (actual)
• Sponsor: Bausch & Lomb Incorporated · Industry
• Sex: All
• Age: 1 Year
• Healthy volunteers: Not accepted

Summary

To evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension, 0.6% (Besifloxacin) administered BID for 3 days compared to vehicle in the treatment of bacterial conjunctivitis.

Conditions

• Bacterial Conjunctivitis

Interventions

Type	Name	Description
DRUG	Besifloxacin	one drop of besifloxacin ophthalmic suspension 0.6% administered to infected study eye(s) BID for 3 days.
DRUG	Vehicle	one drop of the vehicle of besifloxacin ophthalmic suspension administered to infected study eye(s) BID for 3 days.

Timeline

• Start date: 2013-02-01
• Primary completion: 2013-07-01
• Completion: 2013-11-01
• First posted: 2012-12-04
• Last updated: 2014-10-01
• Results posted: 2014-09-17

Locations

1 site across 1 country: United States